title: Effect of purified glutaminase from human ascites fluid on experimental tumor bearing mice.
abstract: Glutamine is the major respiratory fuel and energy source of the rapidly proliferating tumor cells and that is why glutamine clearance by glutaminase therapy provides an opportunity to fight against the neoplasm. Glutaminase from bacterial source was tried on experimental models but had to be excluded because of its limited efficacy. Search for a better glutaminase continued exploiting the mammalian sources. In the present study, glutaminase purified from human ovarian cancer ascites fluid was used in experimental solid and ascites mice model alone and in combination with Cu-Sulphate and heparin. Cumulative findings indicate that the enzyme alone is quite effective in lowering tumor burden and reducing not only the tumor induced angiogenesis, but also an angiogenic inducer, heparin mediated angiogenesis. However, the presence of Cu with the enzyme, amplified the antineoplastic response by improving anti-angiogenic potential and hematological status of the tumor bearing host. Therefore, Cu-glutaminase combination strengthened the hypothesis that together they may provide a better therapeutic regimen in experimental mice tumor model.
authors.affiliation: Dept. of Metabolic Regulation, Chittaranjan National Cancer Institute, Calcutta, India.
authors.forename: P
authors.initials: P
authors.lastname: Bhattacharya
authors.forename: S
authors.initials: S
authors.lastname: Sett
authors.forename: P
authors.initials: P
authors.lastname: Maity
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000201:enzymology*; D001772:Blood Cell Count; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D003300:Copper / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005972:Glutaminase / Q000302:isolation & purification / Q000627:therapeutic use*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000201:enzymology; D013154:Spleen / Q000187:drug effects / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D003300:Copper; D006493:Heparin; D005972:Glutaminase